Iranian Journal of Allergy, Asthma and Immunology 2017. 16(2):120-126.

Oryzatensin-stimulated PBMCs Increase Cancer Progression In-vitro
Meisam Barati, Mehdi Yousefi, Mehrangiz Ebrahimi-Mameghani, Hamed Mohammadi, Balal Brazvan, Hamid Nickho, Mehdi Fouladi, Mohammad Mohammadi


Oryzatensin (ORZ) can reduce potentially IFN-γ secretion by natural killer (NK) cells. Therefore, current study was designed to evaluate the effects of ORZ treatment on peripheral blood mono-nuclear cells (PBMCs) cytokine secretion, proliferation and also to evaluate vascular endothelial growth factor (VEGF) and Matrix Metalloproteinase 9 (MMP-9) expression in HEP-G2 cell line after culture with ORZ-stimulated PBMCs. In this ex-vivo study, PBMCs from apparently healthy male volunteers (n=25) aged 20-30 were isolated by ficoll density gradient. Tetrazolium colorimetric test (MTT assay), ELISA test and real time PCR were performed to evaluate PBMCs proliferation, PBMCs cytokine secretion and the genes expression accordingly. The results of MTT assay showed that ORZ significantly stimulated proliferation of the isolated PBMCs. The results also indicated that ORZ treatment significantly decrease and increase IFN-γ and IL-4 secretion by isolated PBMCs, respectively. Also, VEGF and MMP-9 expression significantly increased in HEP-G2 cells after culture with ORZstimulated PBMCs. The previous studies have introduced ORZ-like peptide for pharmacological purpose and in this study we get to the conclusion that the administration of this peptide may change the immune system response and sensitize target populations to cancer.


Bioactive peptide; Cell proliferation; Oryzatensin; Immune system; Peripheral blood mononuclear cell

Full Text:



1.   Takahashi M, Moriguchi S, Ikeno M, Kono S, Ohata K, Usui H, et al. Studies on the ileum-contracting mechanisms and identification as a complement C3a receptor  agonist  of  oryzatensin,   a  bioactive  peptide derived from rice albumin. Peptides 1996; 17(1):5-12.

2.   Takahashi  M,  Moriguchi  S,  Yoshikawa  M,  Sasaki  R.Isolation and characterization of oryzatensin: a novel bioactive peptide with ileum-contracting and immunomodulating activities derived from rice albumin. Biochem Mol Biol Int 1994; 33(6):1151-8.

3.   Jinsmaa Y, Takenaka Y, Yoshikawa M. Designing of an orally active complement C3a agonist peptide with anti- analgesic   and   anti-amnesic   activity.   Peptides   2001;22(1):25-32.

4.   Ohinata  K,  Suetsugu  K,  Fujiwara  Y,  Yoshikawa  M.M. Barati, et al.Suppression of food intake by a complement C3a agonist [Trp 5]-oryzatensin (5–9). Peptides 2007; 28(3):602-6.

5. Kojima M, Wakai K, Tamakoshi K, Tokudome S, Toyoshima H, Watanabe Y, et al. Diet and colorectal cancer mortality: results from the Japan Collaborative Cohort Study. Nutr Cancer 2004; 50(1):23-32.

6.   Min X, Liu C, Wei Y, Wang N, Yuan G, Liu D, et al.Expression and  regulation  of complement receptors by human   natural   killer   cells.   Immunobiology   2014;219(9):671-9.

7.   Raziuddin  S,  al-Dalaan  A,  Bahabri  S,  Siraj  AK,  al- Sedairy S. Divergent cytokine production profile in Behcet's disease. Altered Th1/Th2 cell cytokine pattern. J Rheumatol 1998; 25(2):329-33.

8.   Theofilopoulos AN, Koundouris S, Kono DH, Lawson BR. The role of IFN-gamma in systemic lupus erythematosus: a challenge to the Th1/Th2 paradigm in autoimmunity. Arthritis Res 2001; 3(3):136-41.

9.   Braumuller H, Wieder T, Brenner E, Assmann S, Hahn M, Alkhaled M, et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 2013; 494(7437):361-5.

10. Egeblad  M,  Werb  Z.  New  functions  for  the  matrix metalloproteinases in cancer progression. Nat Rev Cancer2002; 2(3):161-74.

11. Wang D, Wang H, Guo Y, Ning W, Katkuri S, Wahli W, et al. Crosstalk between peroxisome proliferator-activated receptor δ and VEGF stimulates cancer progression. Proc Natl Acad Sci U S A 2006; 103(50):19069-74.

12. Ducruet AF, Hassid BG, Mack WJ, Sosunov SA, Otten ML, Fusco DJ, et al. C3a receptor modulation of granulocyte infiltration after murine focal cerebral ischemia is reperfusion dependent. J Cereb Blood Flow Metab 2008; 28(5):1048-58.

13. Yuan Y, Adams SD, Dinauer DM, Rosenau CM, Uribe MR, Flegel WA. 98-P: KIR mRNA EXPRESSION IN PBMC AND ENRICHED NK CELLS ASSAYED BY QUANTITATIVE  REAL-TIME  PCR.  Hum  Immunol 2013;74:119.

14. Constant SL. B lymphocytes as antigen-presenting cells for  CD4+  T  cell  priming  in  vivo. J Immunol 1999;162(10):5695-703.

    15. Evans  DE,  Munks  MW,  Purkerson  JM,  Parker  DC.Resting B lymphocytes as APC for naive T lymphocytes:dependence  on  CD40  ligand/CD40.  J  Immunol  2000;164(2):688-97.

16. Kidd P. Th1/Th2 balance: the hypothesis, its limitations,and implications for health and disease. Altern Med Rev2003; 8(3):223-46.

17. Saxena R, Kaur J. Th1/Th2 cytokines and their genotypes as predictors of hepatitis B virus related hepatocellular carcinoma. WJH 2015; 7(11):1572-80.

18. Wang L, Wang Y, Song Z, Chu J, Qu X. Deficiency of interferon-gamma or its receptor promotes colorectal cancer  development.  J  Interferon  Cytokine  Res  2015;35(4):273-80.

19. García-Tuñón I, Ricote M, Ruiz A, Fraile B, Paniagua R, Royuela M. Influence of IFN-gamma and its receptors in human breast cancer. BMC Cancer 2007; 7(1):1.

20. Saxena R, Kaur J. Th1/Th2 cytokines and their genotypes as predictors of hepatitis B virus related hepatocellular carcinoma. World J Hepatol  2015; 7(11):1572-80.

21. Hong M, Jiang Z, Zhou YF. Effects of thermotherapy on Th1/Th2 cells in esophageal cancer patients treated with radiotherapy. Asian Pac J Cancer Prev 2014; 15(5):2359-62.

22. Reiche EM, Nunes SO, Morimoto HK. Stress, depression, the  immune  system,  and  cancer.  Lancet  Oncol  2004;5(10):617-25.

23. Mostafazadeh  A,  Saravi  M,  Niaki  HA,  Drabbels  J, Gholipour HM, Minagar M, et al. HLA-DR1, Circulating Th1/Th2 Cytokines and Immunological Homunculus in Coronary Atherosclerosis.  Iran J Allergy Asthma Immunol 2011; 10(1):11-9.

24. Protti  MP,  De  Monte  L.  Cross-talk  within  the  tumor microenvironment mediates Th2-type inflammation in pancreatic cancer. Oncoimmunology 2012; 1(1):89-91.

25. Chekhonin VP, Shein SA, Korchagina AA, Gurina OI.VEGF in tumor progression and targeted therapy. Curr Cancer Drug Targets 2013; 13(4):423-43.

26. Nishida N, Yano H, Nishida T, Kamura T, Kojiro M.Angiogenesis in cancer. Vasc Health Risk Manag 2006;2(3):213-9.

27. Gialeli  C,  Theocharis  AD,  Karamanos  NK.  Roles  of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 2011; 278(1):16-27.

28. Wu D, Meydani SN. Age-associated changes in immune and inflammatory responses: impact of vitamin E intervention. J Leukocyte Biol 2008; 84(4):900-14.

29. Yuan M, Kiertscher SM, Cheng Q, Zoumalan R, Tashkin DP, Roth MD. Δ 9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. J Neuroimmunol 2002; 133(1):124-31.








  • There are currently no refbacks.

Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.